A

Agenus
D

AGEN

1.59000
USD
-0.04
(-2.15%)
مفتوح الان
حجم التداول
305
الربح لكل سهم
-5
العائد الربحي
-
P/E
-0
حجم السوق
40,241,057
أصول ذات صلة
ACI
ACI
-0.225
(-1.05%)
21.130 USD
AEE
AEE
-0.190
(-0.20%)
96.520 USD
A
AGNC
-0.08000
(-0.99%)
8.03500 USD
ARGX
ARGX
31.48
(5.76%)
578.13 USD
المزيد
الأخبار المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).